Novel mechanisms of macrolide resistance revealed by in vitro selection and genome analysis in Mycoplasma pneumoniae
Open Access
- 22 May 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13
Abstract
Mycoplasma pneumoniaeis an important pathogen causing upper and lower respiratory tract infections in children and other age groups. Macrolides are the recommended treatments of choice forM. pneumoniaeinfections. However, macrolide resistance inM. pneumoniaeis increasing worldwide, which complicates the treatment strategies. The mechanisms of macrolide resistance have been extensively studied focusing on the mutations in23S rRNAand ribosomal proteins. Since the secondary treatment choice for pediatric patients is very limited, we decided to look for potential new treatment strategies in macrolide drugs and investigate possible new mechanisms of resistance. We performed anin vitroselection of mutants resistant to five macrolides (erythromycin, roxithromycin, azithromycin, josamycin, and midecamycin) by inducing the parentM. pneumoniaestrain M129 with increasing concentrations of the drugs. The evolving cultures in every passage were tested for their antimicrobial susceptibilities to eight drugs and mutations known to be associated with macrolide resistance by PCR and sequencing. The final selected mutants were also analyzed by whole-genome sequencing. Results showed that roxithromycin is the drug that most easily induces resistance (at 0.25 mg/L, with two passages, 23 days), while with midecamycin it is most difficult (at 5.12 mg/L, with seven passages, 87 days). Point mutations C2617A/T, A2063G, or A2064C in domain V of23S rRNAwere detected in mutants resistant to the 14- and 15-membered macrolides, while A2067G/C was selected for the 16-membered macrolides. Single amino acid changes (G72R, G72V) in ribosomal protein L4 emerged during the induction by midecamycin. Genome sequencing identified sequence variations indnaK,rpoC,glpK,MPN449, and in one of thehsdS(MPN365) genes in the mutants. Mutants induced by the 14- or 15-membered macrolides were resistant to all macrolides, while those induced by the 16-membered macrolides (midecamycin and josamycin) remained susceptible to the 14- and 15-membered macrolides. In summary, these data demonstrated that midecamycin is less potent in inducing resistance than other macrolides, and the induced resistance is restrained to the 16-membered macrolides, suggesting a potential benefit of using midecamycin as a first treatment choice if the strain is susceptible.Keywords
This publication has 46 references indexed in Scilit:
- Multiple-Locus Variable-Number Tandem-Repeat Analysis of Mycoplasma pneumoniae Clinical Specimens and Proposal for Amendment of MLVA NomenclaturePLOS ONE, 2013
- Carriage of Mycoplasma pneumoniae in the Upper Respiratory Tract of Symptomatic and Asymptomatic Children: An Observational StudyPLOS Medicine, 2013
- Multiclonal Origin of Macrolide-Resistant Mycoplasma pneumoniae Isolates as Determined by Multilocus Variable-Number Tandem-Repeat AnalysisJournal of Clinical Microbiology, 2012
- Mycoplasma Pneumoniae : Susceptibility and Resistance To AntibioticsFuture Microbiology, 2011
- High Prevalence of Macrolide Resistance inMycoplasma pneumoniaeIsolates from Adult and Adolescent Patients with Respiratory Tract Infection in ChinaClinical Infectious Diseases, 2010
- Molecular Mechanisms of Macrolide Resistance in Clinical Isolates of Mycoplasma pneumoniae from ChinaAntimicrobial Agents and Chemotherapy, 2009
- Glycerol Metabolism Is Important for Cytotoxicity of Mycoplasma pneumoniaeJournal of Bacteriology, 2009
- Epidemiology, clinical manifestations, pathogenesis and laboratory detection ofMycoplasma pneumoniaeinfections: Figure 1FEMS Microbiology Reviews, 2008
- Mycoplasma pneumoniae Infection Induces Reactive Oxygen Species and DNA Damage in A549 Human Lung Carcinoma CellsInfection and Immunity, 2008
- Emergence of Macrolide-Resistant Mycoplasma pneumoniae with a 23S rRNA Gene MutationAntimicrobial Agents and Chemotherapy, 2005